MPD1 Antibody

What is PD-1 and what role does it play in the immune system?

PD-1 (Programmed Death-1) is an immune inhibitory receptor expressed on activated B cells, T cells, and myeloid cells that plays a critical role in regulating stimulatory and inhibitory signals in the immune system . It belongs to the CD28/CTLA-4 subfamily within the immunoglobulin superfamily . PD-1 interacts with its ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), which are expressed not only on antigen-presenting cells but also on various types of tumor cells .

The primary function of PD-1 is to trigger a negative immunoregulatory mechanism that prevents overactivation of immune cells and subsequent inflammatory diseases . This inhibitory checkpoint is critical for maintaining self-tolerance and preventing autoimmunity. When PD-1 engages with its ligands, it initiates an inhibitory signaling cascade that downregulates T-cell activation and mediates immune suppression .

What are the different types of anti-PD-1 antibodies and their functional classifications?

Anti-PD-1 antibodies can be functionally classified into two major categories based on their mechanism of action:

• Blocking antibodies: These antibodies prevent the interaction between PD-1 and its ligands (PD-L1/PD-L2), thereby enhancing immune responses. They are widely used in cancer immunotherapy to restore T cell function against tumor cells . Blocking antibodies typically bind to the membrane-distal region of PD-1 .

• Agonistic antibodies: These antibodies mimic or enhance PD-1 signaling, promoting immunosuppression. They recognize the membrane-proximal extracellular region (MPER) of PD-1 and trigger inhibitory signaling, making them potential candidates for treating inflammatory and autoimmune disorders .

Additionally, anti-PD-1 antibodies can be categorized based on their species specificity:

• Human-specific: Bind only to human PD-1 (hPD-1)

• Cross-reactive: Bind to both human and murine PD-1 (mPD-1)

This distinction is particularly important for translational research and preclinical studies in mouse models.

How does an anti-PD-1 antibody's binding epitope determine its functional properties?

The binding epitope of an anti-PD-1 antibody is a critical determinant of its functional properties. Research has revealed a clear dichotomy in epitope recognition and function:

• Membrane-distal region binding: Antibodies that bind to the membrane-distal segments (#1, #2, and #5) of PD-1 function as blocking antibodies . These antibodies interfere with the interaction between PD-1 and its ligands (PD-L1/PD-L2), thereby enhancing immune responses .

• Membrane-proximal extracellular region (MPER) binding: Antibodies that recognize segments in the MPER (particularly segment #7) function as agonists . These antibodies induce immunosuppressive signaling through PD-1 receptor cross-linking .

This epitope-function relationship was consistently observed across 81 anti-human PD-1 monoclonal antibodies in a comprehensive analysis . The binding affinity to human PD-1 showed a positive correlation with the agonistic activity of antibodies, at least in mouse IgG1 subclass clones .

Importantly, agonistic antibodies targeting the MPER do not compete with PD-L1 or PD-L2 for PD-1 binding, allowing for additive immunosuppressive effects when combined with ligands .

Why do some anti-PD-1 antibodies cross-react between species while others don't?

The species cross-reactivity of anti-PD-1 antibodies depends primarily on the conservation of epitopes between human and murine PD-1. There is approximately 77% homology between murine and human PD-L1, resulting in equivalent binding affinities of murine PD-1 (mPD-1) to murine PD-L1 (mPD-L1) and mPD-1 to human PD-L1 (hPD-L1) .

Researchers developing cross-reactive antibodies specifically compare the amino acid sequences and structural homology between human and murine PD-1 to identify conserved epitopes that can be targeted . Using techniques such as alanine scanning and mammalian cell expression cassettes, scientists can map the epitopes of antibodies and determine which regions are conserved across species .

Cross-reactive antibodies are particularly valuable for translational research as they enable:

• Consistent evaluation of antibody effects across murine models and human samples

• Better prediction of clinical outcomes from preclinical studies

• Reduced need for surrogate antibodies in animal studies

The development of such antibodies requires careful epitope selection and in silico modeling to explain different binding modes that allow cross-species reactivity .

How can epitope mapping reveal the binding mechanism of cross-species reactive anti-PD-1 antibodies?

Epitope mapping is a critical methodology for understanding the binding mechanism of cross-species reactive anti-PD-1 antibodies. A comprehensive approach includes:

• Alanine scanning mutagenesis: This technique involves systematically replacing individual amino acids with alanine and testing the impact on antibody binding. For PD-1 antibodies, researchers use PD-1-binding ELISA to quantify changes in binding affinity when specific residues are mutated .

• Mammalian cell expression cassette: This system allows for the expression of mutant PD-1 proteins in mammalian cells, maintaining proper protein folding and post-translational modifications that might be relevant for antibody binding .

• Surface plasmon resonance (SPR): This technique provides affinity ranking of antibody-antigen interactions, supporting the epitope identification from alanine scanning .

• Comparative binding analysis: Researchers compare the epitopes recognized by species-specific antibodies versus cross-reactive antibodies to identify key structural determinants of cross-reactivity .

• In silico modeling: Computational approaches help explain different binding modes of antibodies and provide insights into potential mechanisms of cross-species binding .

For anti-PD-1 antibodies, researchers have used these approaches to identify conserved epitopes between human and murine PD-1, allowing for the development of antibodies that function effectively in both preclinical models and potentially in human applications .

What mechanisms underlie the effect of anti-PD-1 antibodies on macrophage polarization?

Anti-PD-1 antibodies have been demonstrated to redirect macrophages from an immunosuppressive M2 phenotype to a pro-inflammatory M1 phenotype, representing a significant mechanism of action beyond T cell effects. The key mechanisms include:

• Direct PD-1 blockade on macrophages: PD-1 is expressed on tumor-associated macrophages (TAMs), and blocking this receptor with anti-PD-1 antibodies can alter macrophage function and polarization .

• Enhanced M1 macrophage infiltration: Studies using immunohistochemistry (IHC) for CD86 (an M1 marker) have shown a significant increase in M1 macrophages within tumor sites after anti-PD-1 treatment .

• Decreased M2 macrophage presence: CD163+ M2 macrophages (typically observed in the tumor periphery) significantly decrease following anti-PD-1 therapy .

• Differential spatial distribution: Research has revealed that M1 macrophages infiltrate directly into tumors, while M2 macrophages predominantly remain at the tumor periphery, with this distribution shifting after anti-PD-1 treatment .

• Signaling pathway modulation: Anti-PD-1 therapy has been shown to inhibit the p-STAT3/PD-L1 pathway in tumor models, which may contribute to macrophage polarization effects .

A mechanistic study in an osteosarcoma lung metastasis model demonstrated that macrophage depletion significantly compromised anti-PD-1 efficacy, confirming their essential role in mediating therapeutic responses even in the absence of T cells .

How does Fc engineering affect the immunosuppressive activity of agonistic anti-PD-1 antibodies?

Fc engineering plays a crucial role in enhancing the immunosuppressive activity of agonistic anti-PD-1 antibodies through the following mechanisms:

• Enhanced FcγRIIB binding: Fc engineering to improve binding to FcγRIIB significantly enhances the immunosuppressive activity of agonistic anti-PD-1 antibodies .

• Cross-linking mechanism: Agonistic anti-PD-1 antibodies trigger immunosuppressive signaling by cross-linking PD-1 molecules on the cell surface, and this cross-linking is significantly facilitated by Fc receptor interactions, particularly FcγRIIB .

• Different Fc variants: Research has examined multiple Fc variants with different binding properties to FcγRIIB, including X2, X3, and X4 variants . These variants showed:

  • Increased binding to FcγRIIB on THP-1 cells

  • Significantly enhanced immunosuppressive activity in coculture systems with human CD4+ T cells

  • Strong suppression of IFN-γ production in mixed lymphocyte reactions

• Species adaptation: For in vivo studies, Fc regions may need to be adapted to the specific Fc receptor system of the experimental animal model. For example, when using human PD-1 knock-in (hPD-1 KI) mice, antibodies may need to be engineered for optimal interaction with mouse Fc receptors .

Experimental data has demonstrated that Fc-engineered agonistic anti-PD-1 antibodies with enhanced FcγRIIB binding show superior efficacy in suppressing T cell activation and inflammatory responses both in vitro and in vivo .

What experimental models are appropriate for testing anti-PD-1 antibodies with different specificities?

Selecting appropriate experimental models for anti-PD-1 antibody testing depends on the antibody's specificity and the research questions being addressed:

• For human-specific antibodies:

  • Humanized mouse models: Mice with human immune system components

  • Human PD-1 knock-in (hPD-1 KI) mice: Where murine PD-1 genes are replaced with human PD-1 genes

  • In vitro human cell systems: Including primary human T cells, B cells, and THP-1 cell lines

  • Mixed lymphocyte reactions: Using human cells to assess allogeneic responses

• For cross-reactive antibodies:

  • Conventional mouse models: When antibodies recognize both human and murine PD-1

  • Syngeneic tumor models: To evaluate anti-tumor immune responses

  • Human xenograft models in immunocompromised mice: To test effects on human tumors with murine immune components

• For studying macrophage effects of anti-PD-1:

  • Human LM7 osteosarcoma mouse model: Enables assessment of PD-1 blocking effects on NK cells and macrophages in the absence of T cells

  • Macrophage depletion studies: Using clodronate liposomes to confirm the role of macrophages in anti-PD-1 efficacy

• For testing agonistic anti-PD-1 antibodies:

  • Inflammatory disease models: Such as DSS-induced colitis in hPD-1 KI mice

  • Autoimmune models: For evaluating the immunosuppressive potential of agonistic antibodies

Key experimental readouts for these models include:

• Flow cytometry for immune cell phenotyping

• Cytokine production (ELISA, cytometric bead array)

• Histopathology and immunohistochemistry

• Gene expression profiling

• Functional assays (e.g., T cell proliferation, cytotoxicity)

How can anti-PD-1 antibodies that recognize the membrane-proximal region be optimized for treating inflammatory diseases?

Optimizing agonistic anti-PD-1 antibodies that target the membrane-proximal extracellular region (MPER) for inflammatory disease treatment involves several key strategies:

• Epitope selection and optimization:

  • Target segments in the MPER, particularly segment #7, which has shown the strongest agonistic activity

  • Optimize binding affinity, as higher affinity correlates with stronger agonistic activity in mouse IgG1 antibodies

  • Ensure the antibody does not compete with natural ligands, allowing for additive effects with PD-L1/PD-L2

• Fc engineering for enhanced cross-linking ability:

  • Modify the Fc region to enhance binding to FcγRIIB, which is crucial for PD-1 cross-linking and activation

  • Develop variants with progressively improved FcγRIIB binding (e.g., X2, X3, X4 variants) to increase immunosuppressive potency

  • Adapt the Fc region to the species being used in preclinical models to ensure optimal engagement with the relevant Fc receptor system

• Dosing and administration optimization:

  • Determine optimal dosing regimens through careful dose-response studies

  • Explore different routes of administration to maximize efficacy while minimizing systemic immunosuppression

  • Consider combination approaches with conventional anti-inflammatory agents

• Disease-specific targeting:

  • Focus on diseases where PD-1 expression on pathogenic T cells is elevated

  • Target inflammatory conditions where specific effector T cell populations drive pathology

  • Leverage the relative specificity of PD-1 expression on activated immune cells to minimize effects on bystander immune populations

Preclinical testing in models such as DSS-induced colitis in human PD-1 knock-in mice has demonstrated the potential efficacy of this approach, with evidence showing reduced CD4+ T cell expansion in the lamina propria and decreased production of inflammatory cytokines such as IFN-γ and IL-17 .

What techniques are most effective for epitope mapping of anti-PD-1 antibodies?

Effective epitope mapping of anti-PD-1 antibodies involves a combination of complementary techniques:

• Alanine scanning mutagenesis: This systematic approach involves creating a library of PD-1 mutants where individual amino acids are replaced with alanine. Each mutant is then tested for antibody binding using ELISA to identify critical residues involved in the epitope .

• Mammalian cell expression systems: Using mammalian cells to express PD-1 variants ensures proper protein folding and post-translational modifications that might be essential for antibody recognition. This approach is particularly valuable for conformational epitopes .

• Surface plasmon resonance (SPR): This technique provides quantitative measurements of antibody-antigen binding kinetics and affinity. For anti-PD-1 antibodies, SPR can confirm epitope mapping results and rank antibodies by their binding strength .

• Domain swapping: Creating chimeric proteins where domains of human PD-1 are swapped with corresponding murine regions can help identify domains critical for species-specific or cross-reactive binding .

• Competitive binding assays: These determine whether antibodies compete with natural ligands (PD-L1/PD-L2) or with other antibodies of known epitopes .

• Structural analysis: X-ray crystallography or cryo-electron microscopy of antibody-PD-1 complexes provides direct visualization of binding interfaces at atomic resolution, though these methods are more resource-intensive.

For functional classification, researchers have used segment-based approaches, dividing the PD-1 extracellular domain into numbered segments and mapping antibody binding to specific regions . This approach has successfully distinguished blocking antibodies (binding segments #1, #2, and #5) from agonistic antibodies (binding segment #7) .

How can researchers assess the functional effects of anti-PD-1 antibodies in vitro?

Assessing the functional effects of anti-PD-1 antibodies in vitro requires a comprehensive panel of assays that evaluate different aspects of immune cell function:

• T cell activation and proliferation assays:

  • Measure proliferation using CFSE dilution or tritium incorporation

  • Assess activation markers (CD25, CD69) by flow cytometry

  • Quantify IL-2 production as a marker of T cell activation

  • For agonistic antibodies, test the ability to suppress T cell proliferation in the presence of anti-CD3/CD28 stimulation

• Cytokine production measurement:

  • ELISA or cytometric bead array to quantify IFN-γ, IL-2, TNF-α production

  • Intracellular cytokine staining for single-cell analysis of cytokine expression

  • Multi-parameter flow cytometry to correlate cytokine production with cell phenotype

• Cross-linking-dependent assays:

  • For agonistic antibodies, compare soluble antibody effects versus immobilized antibody or Fc receptor-expressing cell-mediated cross-linking

  • Use FcγRIIB-expressing cells (e.g., THP-1) to provide physiological cross-linking

• Mixed lymphocyte reactions (MLR):

  • Co-culture allogeneic B cells and T cells to induce activation

  • Measure the ability of anti-PD-1 antibodies to modulate allogeneic responses

  • Quantify IFN-γ production as a key readout

• Macrophage polarization assessment:

  • Flow cytometry for M1 markers (CD86, iNOS) and M2 markers (CD163, Arg1)

  • Cytokine profiling of macrophage supernatants

  • Gene expression analysis of polarization-associated genes

• Signaling pathway analysis:

  • Western blotting for phosphorylation of SHP-2 and other PD-1 downstream targets

  • Phospho-flow cytometry for single-cell signaling analysis

  • Assessment of TCR-proximal signaling molecules (ZAP-70, Lck)

Appropriate controls are crucial, including isotype controls, PD-L1 fusion proteins, and established blocking antibodies like nivolumab or pembrolizumab for comparison purposes.

What are the potential applications of bispecific antibodies incorporating anti-PD-1 binding domains?

Bispecific antibodies incorporating anti-PD-1 binding domains represent an emerging frontier in immunotherapy research with several innovative applications:

• Targeted PD-1 modulation:

  • PD-1 × tumor antigen bispecifics can selectively block or activate PD-1 signaling in the tumor microenvironment

  • This approach could reduce systemic immune-related adverse events while maintaining anti-tumor efficacy

• Dual checkpoint blockade:

  • PD-1 × CTLA-4 or PD-1 × LAG-3 bispecifics can simultaneously target multiple inhibitory pathways

  • This strategy may overcome resistance mechanisms and enhance efficacy compared to monotherapies or combination therapies

• Enhanced agonistic activity:

  • Bispecific antibodies combining a PD-1 MPER-binding domain with FcγRIIB binding can provide more efficient cross-linking

  • This approach may enhance immunosuppressive activity for autoimmune disease treatment

• MHC-oriented targeted delivery:

  • Bispecific designs similar to T cell engagers can deliver PD-L1 directly to PD-1-expressing T cells

  • This approach has been explored for enhancing immunosuppression in specific T cell populations

• Macrophage reprogramming:

  • PD-1 × CD47 or PD-1 × SIRPα bispecifics could simultaneously block the "don't eat me" signal while enhancing anti-tumor immunity

  • This would combine macrophage-mediated phagocytosis with adaptive immune activation

Research in this area is still developing, but early studies suggest bispecific approaches may offer advantages over monospecific antibodies in terms of efficacy, specificity, and reduced systemic adverse effects. The appropriate design (e.g., IgG-like, tandem scFv, diabody) needs to be carefully considered based on the specific application and desired mechanism of action.

How does the tumor microenvironment affect anti-PD-1 antibody efficacy?

The tumor microenvironment (TME) significantly influences anti-PD-1 antibody efficacy through various mechanisms:

• PD-L1 expression patterns:

  • Heterogeneous PD-L1 expression within tumors creates regions of variable sensitivity

  • Upregulation of PD-L1 via oncogenic signaling (e.g., STAT3 pathway) can enhance response to PD-1 blockade

  • Constitutive versus IFN-γ-induced PD-L1 expression affects predictive value for therapy response

• Macrophage polarization states:

  • Predominance of M2 macrophages in the TME typically indicates immunosuppression

  • Anti-PD-1 therapy can shift the M1/M2 ratio toward pro-inflammatory M1 phenotype

  • The spatial distribution of macrophages (intratumoral vs. peripheral) affects therapeutic outcomes

• FcγR-expressing cells in the TME:

  • The presence of FcγRIIB-expressing cells is crucial for the function of agonistic anti-PD-1 antibodies

  • For blocking antibodies, interaction with certain Fc receptors may lead to antibody-dependent cellular cytotoxicity or phagocytosis of PD-1+ effector cells

• Hypoxia and metabolic factors:

  • Hypoxic conditions can affect antibody penetration and immune cell function

  • Metabolic competition between tumor cells and T cells influences effector function even after PD-1 blockade

• Stromal barriers:

  • Dense stromal elements can impede antibody penetration and immune cell infiltration

  • Remodeling of the extracellular matrix may enhance anti-PD-1 efficacy

Understanding these TME factors has led to combination therapeutic approaches aimed at enhancing anti-PD-1 efficacy, such as combining with agents that reprogram macrophages, reduce tumor hypoxia, or disrupt stromal barriers. Research on macrophage-mediated mechanisms has shown that in some tumor models, the efficacy of anti-PD-1 therapy is primarily dependent on macrophages rather than NK or T cells, highlighting the importance of considering innate immune components in the TME .

What factors should be considered when developing anti-PD-1 antibodies for different disease indications?

Developing anti-PD-1 antibodies for different disease indications requires careful consideration of several key factors:

• Mechanism of action selection:

  • For cancer immunotherapy: Blocking antibodies targeting the membrane-distal region to enhance immune responses

  • For autoimmune/inflammatory diseases: Agonistic antibodies targeting the membrane-proximal region to suppress immune responses

• Species cross-reactivity requirements:

  • For preclinical studies in conventional mouse models: Cross-reactive antibodies binding both human and murine PD-1

  • For studies in humanized models: Human-specific antibodies may be sufficient

  • Consider using epitope mapping and mammalian cell expression systems to identify conserved binding regions

• Fc region optimization:

  • For blocking antibodies: Select Fc regions with minimal effector functions to prevent depletion of PD-1+ effector cells

  • For agonistic antibodies: Engineer Fc regions with enhanced FcγRIIB binding to promote cross-linking and immunosuppressive activity

  • Consider species differences in Fc receptor binding when transitioning between preclinical and clinical studies

• Target cell populations:

  • For T cell-focused approaches: Optimize for activity on CD4+ and CD8+ T cells

  • For macrophage-mediated effects: Consider antibodies that effectively modulate M1/M2 polarization

  • For broader effects: Evaluate impact on multiple immune cell types including B cells and NK cells

• Route of administration and pharmacokinetics:

  • Systemic versus local administration based on indication

  • Half-life considerations (potential for Fc modifications to extend half-life)

  • Tissue penetration properties for solid tumor indications

• Biomarker strategy:

  • Develop companion diagnostics to identify appropriate patient populations

  • For cancer: PD-L1 expression, tumor mutational burden, immune infiltration

  • For autoimmune disease: PD-1 expression on pathogenic T cells

The disease indication fundamentally dictates the antibody properties required. For example, cancer immunotherapy requires blocking antibodies that enhance T cell responses against tumors, while autoimmune disease treatment benefits from agonistic antibodies that suppress pathogenic immune responses .

How do the mechanisms of anti-PD-1 antibodies differ between cancer immunotherapy and autoimmune disease treatment?

The mechanisms of anti-PD-1 antibodies differ fundamentally between cancer immunotherapy and autoimmune disease treatment:

Cancer Immunotherapy (Blocking Antibodies):

• Epitope binding and mechanism:

  • Bind to membrane-distal regions of PD-1 (segments #1, #2, and #5)

  • Block interaction between PD-1 and its ligands (PD-L1/PD-L2)

  • Prevent inhibitory signaling in tumor-reactive T cells

• Cellular effects:

  • Enhance T cell activation, proliferation, and effector function

  • Increase production of effector cytokines (IFN-γ, TNF-α)

  • Promote infiltration of effector T cells into tumors

  • Redirect macrophages from immunosuppressive M2 to pro-inflammatory M1 phenotype

• Molecular pathways:

  • Prevent PD-1-mediated dephosphorylation of signaling molecules

  • Block inhibition of the PI3K/Akt and Ras/MEK/Erk pathways

  • Inhibit p-STAT3/PD-L1 pathway in tumors

Autoimmune Disease Treatment (Agonistic Antibodies):

• Epitope binding and mechanism:

  • Bind to membrane-proximal extracellular region (MPER), particularly segment #7

  • Do not compete with PD-L1/PD-L2 for binding to PD-1

  • Cross-link PD-1 molecules to induce inhibitory signaling

• Cellular effects:

  • Suppress T cell activation and proliferation

  • Reduce production of inflammatory cytokines

  • Decrease CD4+ T cell expansion in inflammatory sites

  • Lower production of IFN-γ and IL-17 in disease models

• Molecular requirements:

  • Require Fc receptor-mediated cross-linking, particularly via FcγRIIB

  • Enhanced activity with Fc engineering to improve FcγRIIB binding

  • Trigger PD-1 immunosuppressive signaling pathways independent of ligand binding

This distinct mechanistic dichotomy underscores the versatility of targeting the PD-1 pathway, allowing for both enhancement and suppression of immune responses based on the antibody design and epitope targeting. The differences extend to optimal antibody properties, including isotype selection, Fc engineering requirements, and even routes of administration for different disease indications .